Jean-Paul Kress
Chief Executive Officer presso MORPHOSYS AG
Patrimonio netto: - $ in data 31/03/2024
Posizioni attive di Jean-Paul Kress
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MORPHOSYS AG | Chief Executive Officer | 01/09/2019 | - |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Director/Board Member | 03/01/2018 | - |
| President | 03/01/2018 | - | |
| Chief Executive Officer | 03/01/2018 | - |
Storia della carriera di Jean-Paul Kress
Precedenti posizioni note di Jean-Paul Kress
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Chairman | 21/06/2019 | 23/06/2023 |
| Independent Dir/Board Member | 21/06/2019 | 23/06/2023 | |
| QUANTUM GENOMICS | Director/Board Member | 01/06/2018 | 24/06/2019 |
| BIOGEN INC. | Corporate Officer/Principal | 01/06/2017 | 01/01/2018 |
| SAREPTA THERAPEUTICS, INC. | Director/Board Member | 30/09/2015 | 06/06/2017 |
| Independent Dir/Board Member | 30/09/2015 | 06/06/2017 | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/09/2015 | 01/06/2017 |
Sanofi Pasteur MSD SNC
 Sanofi Pasteur MSD SNC Pharmaceuticals: MajorHealth Technology Sanofi Pasteur MSD SNC is engaged in the wholesale of pharmaceutical products. The company was founded on August 16, 1993 and is headquartered in Lyon, France. | Chief Executive Officer | 01/07/2011 | 01/09/2015 |
| President | 01/07/2011 | 01/09/2015 |
Formazione di Jean-Paul Kress
| École Normale Supérieure | Graduate Degree |
| Faculté De Médecine Necker Enfants Malades Université | Doctorate Degree |
Statistiche
Distribuzione geografica
| Francia | 6 |
| Stati Uniti | 5 |
| Germania | 2 |
Posizioni
| Director/Board Member | 3 |
| Chief Executive Officer | 3 |
| Independent Dir/Board Member | 2 |
Settori
| Health Technology | 9 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| BIOGEN INC. | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| MORPHOSYS AG | Health Technology |
| QUANTUM GENOMICS | Health Technology |
| Aziende private | 4 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Health Technology |
Sanofi Pasteur MSD SNC
Sanofi Pasteur MSD SNC Pharmaceuticals: MajorHealth Technology Sanofi Pasteur MSD SNC is engaged in the wholesale of pharmaceutical products. The company was founded on August 16, 1993 and is headquartered in Lyon, France. | Health Technology |
- Borsa valori
- Insiders
- Jean-Paul Kress
- Esperienza
